marijuana stocks news

Cara Therapeutics to Webcast Presentation at Canaccord Genuity 36th Annual Growth Conference

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 36thAnnual Growth Conference on Thursday, August 11, 2016, at 12:30 p.m. ET in Boston.

A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website atwww.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

MariMed Inc. (MRMD) Completes Acquisition of Kind Therapeutics USA

MariMed Completes Acquisition of Kind Therapeutics USA, a Maryland Vertically Integrated Cannabis…

Premier Health Group (PHGI) (PHGRF) Binding LOI to Acquire Two Operating Pharmacies in Metro Vancouver

Premier Health Announces Binding LOI to Acquire Two Operating Pharmacies in Metro…

Namaste Technologies Inc. (NXTTF) Announces 2018 Board of Director Nominees

Namaste Announces 2018 Board of Director Nominees Namaste Technologies Inc. (“Namaste” or…

Lexaria Bioscience Corp. (LXRP) Receives Conditional Ethics Board Approval

Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH…